Skip to main navigation
MBX Bio Logo
  • Our Science
    • How PEPs™ Work
    • Development Programs
  • Platform
    • Our Pipeline
      • Canvuparatide
      • MBX 4219
      • MBX 5765
      • MBX 6180
  • Patients
    • Current Clinical Trials
    • Patient Stories
    • Resources & Advocacy
  • About Us
    • Mission
    • Core Values
    • Leadership Team
    • Board of Directors
    • Scientific Advisory Board
  • Investors
    • News & Events
      • News Releases
      • Events
      • Presentations
    • Corporate Governance
      • Governance Overview
      • Board of Directors
      • Leadership Team
      • Committee Composition
    • Financial Information
      • SEC Filings
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Shareholder Services
      • Investor FAQs
      • Email Alerts
      • RSS Feeds
      • Contact IR
  • Careers
  • Contact Us

Presentations

Corporate Presentations

August 6, 2026
MBX August 2026 Presentation 1.8 MB
June 12, 2026
MBX ENDO 2026 Presentation 2.9 MB
May 11, 2026
MBX-May 2026 Obesity Day Presentation – Final 1.5 MB
September 23, 2025
Once-Weekly Canvuparatide Avail™ Phase 2 Trial Topline Results 1.1 MB

Scientific Publications/Presentations

Efficacy and Safety of Once-Weekly Canvuparatide in Patients With Hypoparathyroidism: Results From Avail, a Phase 2, Double-Blind, Placebo-Controlled, Randomized Clinical Trial
Once-Weekly Canvuparatide in Patients With Hypoparathyroidism: Interim Analysis of the Open-Label Extension to the Phase 2, Double-Blind, Placebo-Controlled Avail Study
MBX 2109, A Once-Weekly Parathyroid Hormone Replacement Therapy Prodrug: Phase 1, First-In-Human, Randomized Trial
MBX Bio Logo

MBX Biosciences is a biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities.

FOLLOW US

Facebook Logo Twitter Logo LinkedIn Logo

©2026 MBX Bio. All Rights Reserved.

  • Contact Us
  • Privacy Policy
  • Terms of Use

Website design by Mentus

©2026 MBX Bio. All Rights Reserved.

Website design by Mentus